3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Multiple Myeloma
238
Precursor Cell Lymphoblastic Leukemia-Lymphoma
46
Recurrence
35
Burkitt Lymphoma
23
Neoplasms
20
Neoplasms, Plasma Cell
17
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
15
Immunoglobulin Light-chain Amyloidosis
13
Leukemia
12
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
10
Lymphoma
10
Lymphoma, Large B-Cell, Diffuse
9
Lung Neoplasms
9
Carcinoma, Non-Small-Cell Lung
9
Prostatic Neoplasms
8
Leukemia, Biphenotypic, Acute
8
Neoplasm Metastasis
7
Lymphoma, Non-Hodgkin
7
Breast Neoplasms
7
Lymphoma, B-Cell
6
Smoldering Multiple Myeloma
5
Nausea
5
Leukemia, Myeloid, Acute
5
Hodgkin Disease
5
Brain Neoplasms
5
Waldenstrom Macroglobulinemia
4
Neoplasm, Residual
4
Lymphoma, T-Cell, Peripheral
4
Lymphoma, Mantle-Cell
4
Amyloidosis
4
Interventions
Etoposide
3
daratumumab
2
Vincristine
2
Prednisone
2
Doxorubicin
2
Cyclophosphamide
2
varlilumab
1
prednylidene
1
pomalidomide
1
deltacortene
1
carmustine, poliferprosan 20 drug combination
1
belantamab mafodotin
1
Specimen Handling
1
Rituximab
1
Peripheral Blood Stem Cell Transplantation
1
Nivolumab
1
Melphalan
1
Magnetic Resonance Spectroscopy
1
Immunoglobulin G
1
Disulfides
1
Dexamethasone
1
Cytarabine
1
Carmustine
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Plasmablastic Lymphoma
×
Dexamethasone
×
1 year
×
Clear all
NCT04915248
2026-06-02
FIL_DALYA
Fondazione Italiana Linfomi - ETS
Phase 2
Recruiting
28 enrolled